Castle Biosciences: Inflection Into Profitability
Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. CSTL faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field.
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Sung Nam - Scotiabank Subbu Nambi - Guggenheim Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences Second Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.70 per share a year ago.
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top 5 Health Care Stocks That May Explode In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
